IMAB Jul 2024 2.500 put
| Previous close | 0.8000 |
| Open | 0.8000 |
| Bid | 0.0000 |
| Ask | 1.3000 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.8000 - 0.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 21 |
Simply Wall St.While private equity firms own 21% of I-Mab (NASDAQ:IMAB), retail investors are its largest shareholders with 59% ownership
Key Insights Significant control over I-Mab by retail investors implies that the general public has more power to...
PR NewswireI-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team.
- PR Newswire
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY). The collaboration will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody jointly developed by I-Mab a
